The Dollar's Collapse Party Might Be Ending -- HSBC Says the Real Bubble Is Forming Now
Warning! GuruFocus has detected 6 Warning Sign with HSBC.
The dollar's fall has been fueled by U.S. tariff drama, rising global de-dollarization talk, and general unease around Washington's policy direction under Trump. But HSBC notes that some of the initial catalystslike the shock from the April tariff announcementare now old news. What's more, historical correlations between the dollar and U.S. yields are starting to re-emerge, which could be an early sign that the dollar is bottoming out. Equities and yields are also moving in tandem again, hinting at a broader return to fundamentals.
Still, the bears aren't out of ammo just yet. HSBC highlights scenarios that could keep the pressure on: more policy chaos, a faster-than-expected global rebound, or even leadership changes at the Fed. While none of these are base case assumptions, Mackel's team urges investors to stay alert. Bubbles don't last forever, they wrote. And if this really is an anti-dollar bubble, the unwinding could be just as sharp.
This article first appeared on GuruFocus.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
Revvity Inc (RVTY) Q2 2025 Earnings Call Highlights: Strong Software Growth and Strategic Share ...
Revenue: $720 million in Q2, 3% organic growth. Adjusted EPS: $1.18, above expectations. Life Sciences Segment Growth: 4% organic growth. Diagnostics Segment Growth: 2% organic growth. Signals Software Growth: Over 30% organic growth. Free Cash Flow: $115 million in Q2, 83% conversion of adjusted net income. Operating Margin: 26.6% adjusted operating margin, down 210 basis points year over year. Share Repurchase: $293 million worth of shares repurchased in Q2. Full-Year Organic Growth Outlook: 2% to 4% range. Full-Year Adjusted EPS Outlook: $4.85 to $4.95. Net-Debt-to-Adjusted-EBITDA Ratio: 2.6 times. Adjusted Tax Rate: 19.1% in Q2. Warning! GuruFocus has detected 5 Warning Signs with RVTY. Release Date: July 28, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Revvity Inc (NYSE:RVTY) achieved 3% organic growth in Q2 2025, in line with expectations, driven by strong performance in the Life Sciences segment. The Signals Software franchise experienced approximately 30% growth, setting a new record for orders in a single quarter. Revvity Inc (NYSE:RVTY) reported adjusted EPS of $1.18, which was above expectations and guidance. The company generated $115 million in free cash flow during the quarter, maintaining a solid 90% conversion rate year-to-date. Revvity Inc (NYSE:RVTY) repurchased nearly $300 million worth of stock in Q2, bringing total repurchases to nearly $450 million for the first half of the year. Negative Points The Diagnostics segment faced challenges in China due to changes in hospital lab reimbursement policies, impacting the Immunodiagnostics business. Revvity Inc (NYSE:RVTY) lowered its full-year organic growth outlook to 2% to 4%, down 1% from prior expectations. The company anticipates a meaningful pullback in its Immunodiagnostics business in China for the remainder of the year. Operating margins were pressured by lower volumes of high-margin diagnostic tests and recent changes in FX rates. The academic and government customer segment continued to show weakness, with revenue declining in the low single digits year over year. Q & A Highlights Q: Can you explain the guidance change related to organic growth, particularly in China, and whether other factors like VBP are involved? A: (Prahlad Singh, CEO) The majority of the impact is from the DRG policy in China, which affects multiplex tests. This policy reduces test volumes, but in the long term, it may lead to more single-plex tests, which are more expensive. We are working with stakeholders to potentially reverse these changes due to their impact on patient care. Q: Regarding margin changes, what are your expectations for 2026 margins, and what growth assumptions are they based on? A: (Maxwell Krakowiak, CFO) We expect a baseline operating margin of 28% for 2026, with margin expansion depending on organic growth levels. Typically, with high single-digit growth, we expect a 75 basis point margin expansion, and with mid-single-digit growth, about 50 basis points. Q: What are the revenue pacing assumptions for this year, and how do you see the impact of NIH funding and year-end budget flush? A: (Maxwell Krakowiak, CFO) We expect normal seasonality with a high single-digit ramp in both Life Sciences and Diagnostics. The fourth quarter will see a ramp-up in gel and larger volume in Signals Software. We assume academic and government funding will remain weak for the rest of the year. Q: Can you provide insights into the Life Sciences segment's performance, particularly reagents and instruments, and any guidance changes? A: (Prahlad Singh, CEO) Pharma-biotech showed stability with mid-single-digit growth, and our Life Sciences reagents business has grown for five consecutive quarters. While capital equipment spending is impacted, we remain optimistic about the reagents business. Q: How is the Software segment performing, and what are the expectations for growth in the second half? A: (Prahlad Singh, CEO) The Signals Software business had a record quarter with 32% organic growth. We focus on net retention, ARR, and APV, with strong SaaS bookings. We expect continued growth due to investments and new product launches. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
22 minutes ago
- Business Insider
Interactive Brokers (IBKR) Considers Launching a Stablecoin Product for Customers
Investing platform Interactive Brokers (IBKR) is considering launching a stablecoin product for its customers, according to Reuters. Founder and former CEO Thomas Peterffy said in an interview that while no final decisions have been made, the company is exploring ways to let clients use stablecoins for 24/7 deposits into brokerage accounts. This comes as regulations for cryptocurrencies ease under the Trump administration and as more financial firms look to meet growing demand for faster and cheaper transfers between traditional markets and crypto ecosystems. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. One option that is being considered is allowing customers to fund their accounts with stablecoins issued by other financial institutions, if those issuers are considered credible. By integrating stablecoins, Interactive Brokers would be joining other major players entering the digital asset space. Indeed, earlier this month, fintech firm Paxos announced the launch of its Global Dollar stablecoin—which is backed by companies such as Robinhood Markets (HOOD), Mastercard (MA), and Kraken—in the European Union. Several large U.S. banks have also talked about stablecoins in recent earnings calls by saying that new legislation creates opportunities for digital assets to become more deeply embedded in the financial system. As a result, for investors, this suggests that stablecoins may become a new growth catalyst for financial institutions and are something worth keeping an eye on. Is IBKR Stock a Good Buy? Turning to Wall Street, analysts have a Strong Buy consensus rating on IBKR stock based on five Buys, one Hold, and zero Sells assigned in the past three months, as indicated by the graphic below. Furthermore, the average IBKR price target of $67.92 per share implies 3.6% upside potential.
Business Insider
37 minutes ago
- Business Insider
Walmart Stock (WMT) Widening Gap on Rivals Despite Holiday Price Hikes Ahead
Shares in U.S. retail giant Walmart (WMT) were marked higher today as it said it expects to gain market share from tariff turmoil this year. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Market Share According to a note from analysts at Jefferies, even though Walmart has already raised prices on a range of goods given the uncertainty around President Trump's tariffs, it still expects to gain market share from its peers. Following a recent meeting with Walmart's head of investor relations, Steph Wissink, Jefferies said in a note that 'prices increased as the tariffs were implemented in April' for perishables and other items sourced from Central America. The firm noted that in June, prices also began to rise on 'infrequently purchased general merchandise items that were previously trending deflationary.' Such macro risks are key for consumer-facing stocks like Walmart as one can see below. Value Focus Jefferies said Walmart (NYSE:WMT) expects further increases on 'seasonal items heading into Halloween and the winter holidays,' but remains committed to its value-focused strategy: 'WMT remains committed to its Everyday Low Price strategy and taking less price than its peers,' it said. Despite inflationary pressures, Jefferies said Walmart believes that the U.S. consumer has been relatively resilient. 'We would categorize the US consumer as consistent,' said Jefferies, though Walmart has seen 'emerging signs of trade down and substitution.' It is understood that Walmart plans to aggressively compete during the upcoming back-to-school season by 'widening its price gaps on key, high-frequency items,' which it expects will boost share as consumers become more price-sensitive. Walmart is already performing well against its peers as can be seen below. In terms of inventory, Jefferies said Walmart expects it to jump in the second quarter given that the 'actual tariff rate is higher than originally expected.' However, analysts said they are 'not concerned about the health of the inventory.' Jefferies expects the company to reaffirm its full-year outlook, stating, 'We believe that WMT is well-positioned to achieve its guidance,' even as tariff-related volatility limits near-term upside. Jefferies has a Buy rating on the stock and a $120 price target. Is WMT a Good Stock to Buy Now? On TipRanks, WMT has a Strong Buy consensus based on 28 Buy ratings. Its highest price target is $120. WMT stock's consensus price target is $111.33, implying a 14.06% upside.
